

Date: 12/06/2025

To
BSE Limited
Dept. of Corporate Services,
Floor 25, PJ Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526445

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 12th June, 2025

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to our intimation letters dated 27th May 2025 and 9th June, 2025, we wish to inform that the Board of Directors, at their meeting of held today i.e., 12th June 2025, has inter-alia, approved the following:

- i. Audited Financial Results (Standalone) for the quarter and year ended March 31, 2025 together with the Reports of the Statutory Auditors with unmodified opinion (Annexure 1).
- ii. Resignation of V Santhanakrishnan, as Company Secretary and Compliance Officer, with effect from June 13, 2025 (Disclosure is provided as Annexure-II)

Further, the meeting is adjourned for tomorrow (13/06/2025) for considering and approving the Audited Financial Results (Consolidated) for the quarter and year ended March 31, 2025 together with the Reports of the Statutory Auditors.

The meeting commenced at 07:00 p.m. and adjourned for tomorrow at 11:10 p.m.

We request you to kindly take the same on your records.

Thanking you,

Yours faithfully,

For Indrayani Biotech Limited

Swaminathan G
Whole-time Director
DIN: 02481041

Encl.: as above

Independent Auditor's Report on Standalone Financial Results and Year to Date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of **Indrayani Biotech Limited**
Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Indrayani Biotech Limited (the company) for the year ended 31st March 2025 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income (loss) and other financial information for the year ended 31st March 2025.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143 (10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion on the standalone financial results.

Management's Responsibilities for the Standalone Financial Results

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act respect to the preparation of these standalone financial results that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the LODR Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from

fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

Attention is drawn to the fact that figures for the last quarter ended March 31, 2025 and the corresponding quarter ended in the previous year as reported in this Statement are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

for Venkatesh & Co

Chartered Accountants

FRN: 04636S



CA Desikan G

Partner

M No: 219101

ICAI UDIN: 25219101BMICLV6956

Chennai, 12th June 2025

INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032

Audited Standalone Profit and Loss for the quarter and year ended 31st March 2025

(Rs in Lakhs except EPS)

S. No.	Particulars	Quarter ended			Year ended	
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
I	Revenue from Operations	928.31	818.82	1,579.93	3,776.91	6,232.34
II	Other Income	93.41	66.21	344.58	351.60	361.88
III	Total Income	1,021.72	885.03	1,924.51	4,128.51	6,594.22
IV	Expenses					
	Cost of Materials consumed	279.66	334.29	762.38	1,478.43	3,515.38
	Employee Benefit Expense	330.35	269.37	490.45	1,323.68	1,569.08
	Finance Cost	239.46	152.49	247.25	732.10	482.76
	Depreciation and amortization expense	6.41	32.34	35.46	102.49	144.76
	Other expenses	145.60	82.36	226.57	427.18	581.31
	Total Expenses	1,001.48	870.85	1,762.11	4,063.88	6,293.29
V	Profit / (loss) before exceptional items and tax	20.24	14.18	162.40	64.63	300.91
VI	Exceptional Items					
	Add : Share of profit In Associates	-	-	-	-	-
VII	Profit / (loss) before tax	20.24	14.18	162.40	64.63	300.91
VIII	Current Tax Expense	-11.17	3.57	54.17	-	54.17
IX	Deferred Tax Expense	-80.00	-	101.00	-80.00	101.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	111.41	10.61	7.23	144.63	145.74
	Profit (Loss) for the period from discontinued operations	-	-	-	-	-
XI	Profit (Loss) for the period (VII-VIII)	111.41	10.61	7.23	144.63	145.74
XII	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XIII	Total Comprehensive Income for the period (XII+XI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	111.41	10.61	7.23	144.63	145.74
	Paid up equity share capital (Face value of Rs.10 each)	4,553.63	4,553.63	4,553.63	4,553.63	4,553.63
XIV	Earnings Per Share:					
	(1) Basic (in Rs.)	0.25	0.02	0.08	0.32	0.37
	(2) Diluted (in Rs.)	0.25	0.02	0.08	0.32	0.37

Notes:

- The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12th June 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com)
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the quarter.

for and on behalf of the Board of Directors of
Indrayani Biotech Limited

Swaminathan Govindarajan
Whole-time Director
DIN: 02481041

M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

**BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,
GUINDY, CHENNAI, 600032**

Standalone Balance sheet as on 31st Mar 2025

Rs. In Lakhs

Particulars	As at 31 Mar 2025	As at 31 Mar 2024
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	1,282.52	1,782.42
Capital Work in Progress	1,809.07	1,802.91
Goodwill	383.53	383.53
Financial assets		
(i) Investments	961.40	955.81
(ii) Other financial assets	462.61	419.52
Non-current tax assets	106.17	106.17
Other Non Current Assets		-
Total non-current assets	5,005.30	5,450.36
CURRENT ASSETS		
Inventories	168.60	192.32
Financial assets		
(i) Trade receivables	1,645.91	1,759.63
(ii) Cash and cash equivalents	6.21	26.29
(iii) Loans	4,624.30	3,921.59
(iv) Other Financial Assets	392.25	339.90
Current Tax Assets (Net)	189.49	136.05
Other current assets	1,035.71	774.69
Total current assets	8,062.47	7,150.47
TOTAL ASSETS	13,067.77	12,600.83
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	4,553.63	4,553.63
Other equity	979.52	897.90
Total equity	5,533.15	5,451.53
NON-CURRENT LIABILITIES		
Financial liabilities		
(i) Borrowings	1,364.13	1,487.95
(ii) Lease Liabilities	-	406.70
Deffered Tax liabilities	22.38	102.38
Total non-current liabilities	1,386.51	1,997.03
CURRENT LIABILITIES		
Financial liabilities		
(i) Borrowings	4,801.97	4,371.83
(ii) Lease Liabilities		79.34
(ii) Trade payables		
Total outstanding dues to micro enterprises and small enter		-
Total outstanding dues of creditors other than micro	855.67	272.34
enterprises and small enterprises		
(ii) Other Financial Liabilities		-
Other current liabilities	99.92	138.36
Provision	390.55	290.38
Total current liabilities	6,148.11	5,152.25
TOTAL EQUITY AND LIABILITIES	13,067.77	12,600.83

For Indrayani Biotech Limited

Swaminathan Govindarajan
Whole-time Director
DIN: 02481041

M/s. INDRAYANI BIOTECH LIMITED
CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

Standalone Cash Flow Statement for the year ended 31/03/2025

Rs. In Lakhs

Particulars	As on 31-Mar-25	As on 31-Mar-24
Cash Flows From Operating Activities:-		
Net Profit after Taxation	64.63	300.91
Adjustment for Non cash items		
Add : Impairment/ Write off of Property Plant and Equipment and Capital Work in Progress	-	-
Add : Depreciation	102.49	144.76
Less : Interest Income Notional (As per Ind AS 109)	-	(4.18)
Less : Notional Income	(9.72)	-
Add: Interest Expenses Notional as per applicable IndAS	-	30.12
Adjustment for Non Operating activities		
Add : Interest Paid (Including Interest on Lease Liabilities)	732.10	452.64
Less : Interest income	-	-
Cash Flow Before Working Capital changes:-	889.50	924.25
Decrease (Increase) in Inventories	23.72	(5.87)
Decrease (Increase) in Trade receivables	113.72	(136.93)
Decrease (Increase) in Current Tax Assets	(53.44)	(25.65)
Decrease (Increase) in Other Financial Assets	(52.35)	61.46
Decrease (Increase) in other current assets	(261.02)	(87.84)
(Decrease) Increase in Short term borrowings	430.14	1,820.63
(Decrease) Increase in Financial liabilities	-	(228.35)
(Decrease) Increase in Trade payables	583.33	115.90
(Decrease) Increase in Other Current liabilities	(38.44)	67.32
(Decrease) Increase in Provisions	100.17	103.98
Cash Flow Before Tax and Extraordinary Items:-		
Income Taxes Paid	-	-
Net Cash Flow From Operating Activities	1,735.34	2,608.91
Cash Flow from Investing Activities:-		
Less : Purchase of Capital Assets	(85.07)	(634.37)
Less : Purchase of Investments	(5.59)	(157.19)
Add : Rental Receipts	-	-
Add : Amount of Interest Received	-	-
Less : Sale of Capital Assets	-	-
Decrease (Increase) in Loans and advances & Other assets	(43.09)	65.68
Net Cash flow used in Investing Activities	(133.75)	(725.88)
Cash Flow from Financing Activities:-		
Increase in Borrowings	(123.82)	511.94
Interest Income Notional (As per Ind AS 109)	-	4.18
Increase in Share capital	-	205.91
Issue of Share Warrant	(63.06)	-
Interest expense(Including Interest on Lease Liabilities)	(732.10)	(482.76)
Repayment of Lease Liabilities	-	(84.83)
Loan to Group Companies	(702.71)	(2,058.12)
Security Premium Received	-	257.38
Issue Expenses Paid	-	(272.36)
Decrease in borrowings	-	-
Net Cash Flow From Financing Activities	(1,621.67)	(1,918.64)
Net Increase/(Decrease) in Cash and Cash Equivalents:-		
(Opening Balance)	26.29	61.90
Net Cash Flow during the year	(20.08)	(35.61)
(Closing Balance)	6.21	26.29

For Indrayani Biotech Limited

Swaminathan Govindarajan
Whole-time Director
DIN: 02481041

Annexure-II

The Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023:

Resignation of Mr. V. Santhanakrishnan (Membership no. A54146) as Company Secretary and Compliance officer:

Sl.No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation from the post of Company Secretary of the Company due to pursuing other opportunities
2	Date of appointment/cessation applicable) & term of appointment;	June 13, 2025
3	Brief profile (in case of appointment)	Not applicable
4	Disclosure of relationships between directors (in case of appointment of a director).	Not applicable



My resignation

1 message

Santhana Krishnan <vskrsna@gmail.com>

To: sayee_sundar@yahoo.com, swami nathan <gsnathan10@gmail.com>

Cc: dhinakaran@indrayani.com, marysujatha@indrayani.com

Fri, 25 Apr, 2025 at 12:10

25th April 2025

From

V Santhanakrishnan
E1, Lakshmi Nagar, Agaramthen,
Mappedu post, East Tambaram-600126

To

The Board of Directors
Indrayani Biotech Limited
Module 33, 3rd floor, Block 1,
SIDCO electronic complex
Thiru vi ka industrial estate
Guindy, Chennai 600032
Through: Chief Financial Officer and HR

Dear Sir,

Sub: My resignation-reg

As I am pursuing other opportunities, I wish to tender my resignation from this esteemed organisation. I hereby take my this opportunity to thank my superiors and colleagues for their support and co-operation extended to me in my tenure in this organisation. I humbly request you to relieve me from all my responsibilities on or before 10th June 2025 and issue necessary relieving and experience certificate.

Thanking you.

Yours truly,

V Santhanakrishnan

